Go to Page # Page of 40

Delivering cost-effective innovation based on already-approved proteins

 Gerard Soula PhD, Olivier Soula PhD, Valerie Danaguezian, Remi Soula PhD, Steve Daly, Stan Glezer MD
  13th-Mar-2018
Description: This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompanying this document provided by the Company, any question and answer session following that oral presentation and any further information that may be made available in connection with the subject matter contained herein.
Views: 1160
Domain: Medical
Category: Biotech/Pharma
Contributing Organization: ADOCIA
 ‐ More of their Presentations
Space is limited, so register today!
Contents:
CORPORATE PRESENTATION
JANUARY 2018

INTRO

Disclaimer

This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include
this document, any oral presentation accompanying this document provided by the Company ... See more

Recent Presentations

Plenary Session: Research on Dementia

Plenary session: Follow up analysis suggested that the probable amnestic storage group had the highest risk of conversion to dementia. Having 8.5 times more risk to convert to deme

...
14 December, 2018

her2 cd3 bispecific

Recombinant Anti-TNF & Anti-IL17A Bispecific Antibody (DVD-Ig).The DVD-Ig format that was used comprised a whole TNF-binding 'IgG' (with Fc region) to which additional variable reg

Bella Smith
13 December, 2018
...
13 December, 2018